Saturday 7 November 2026 Export ARMP’s income statement to Excel — free account

Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024.

Revenue: +15.7%
EPS: +548.9%
Free cash flow: −18.0%
Total debt: +152.4%

Quarter to June 2026, against a year earlier

3.37 0.37 +12.33%

Follow ARMP

Alert me

Market cap: $111.5M
P/E: 0.0×
Fwd P/E: −1.8×
Dividend yield: —
F-score: 3/9
Altman Z: −10.15
Beneish M: −12.48
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 67.62%

Capital & Financial Ratios $m

Size

Market Cap 111.54

Revenue ttm 5.54

Net income ttm (192.18)

Free cash flow ttm (25.79)

Net debt Q 259.56

Valuation

P/E 0.00

Forward P/E (1.76)

Price / sales 22.34

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 0.11

Debt / equity Q (1.23)

Interest coverage Q (1.55)

Growth

Revenue growth Q +15.72%

Operating income growth Q −50.67%

EPS, this year +61.15%

EPS, next year A +22.52%

Revenue, next year A −13.34%

EPS, past 5 yrs —

EPS, next 5 yrs A +38.99%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 28.85%

10-year low 10-year high

EV/Sales against its own 10 years 66.17%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	9	9	24
Receivables	3	1	0	3
Inventory	—	—	—	—
Other	—	—	—	—
	19	11	11	27

	2023	2024	2025	Q'26
Payables	6	2	2	2
ST’ Debt	—	39	—	241
Other	1	1	0	0
	16	48	9	250

Compound Annual Growth %

	10y	5y	3y
Sales	—	42.90%	(3.80%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.48 Actual −0.27

−0.63 −0.50 −0.38 −0.26 −0.13

Q2 FY25 Beat +0.07

Q3 FY25 Met 0.00

Q4 FY25 Miss −0.32

Q2 FY26 Beat +0.21

Q3 FY26 — Nov 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY25	−0.39	−0.32	Beat by 0.07
Q3 FY25	−0.42	−0.42	Met by 0.00
Q4 FY25	−0.19	−0.51	Miss by 0.32
Q2 FY26	−0.48	−0.27	Beat by 0.21
Q3 FY26	−0.57	—	Reports 11 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.16)	(0.27)	—	—	—
’25	(0.20)	(0.45)	(0.74)	(3.43)	(4.80)
’24	(0.69)	0.15	(0.15)	(0.23)	(0.89)
’23	(0.40)	(0.06)	(0.86)	(0.55)	(1.91)
’22	(0.30)	(0.26)	(0.24)	(0.29)	(1.08)
’21	(0.27)	(0.25)	(0.22)	(0.23)	(0.96)
’20	(0.49)	(0.26)	(0.31)	(0.36)	(1.35)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	3	—	—	—
’25	0	2	1	1	5
’24	1	—	3	1	5
’23	1	1	1	2	5
’22	1	2	1	1	6
’21	1	1	1	1	4
’20	—	0	0	1	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(9)	—	—	—
’25	(8)	(7)	(4)	(7)	(26)
’24	(11)	(10)	(9)	(8)	(38)
’23	(18)	(12)	(10)	(8)	(47)
’22	(4)	(8)	(10)	(10)	(32)
’21	(5)	(5)	(5)	(9)	(24)
’20	(4)	(4)	(4)	(6)	(18)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(9)	—	—	—
’25	(8)	(7)	(5)	(7)	(26)
’24	(11)	(12)	(9)	(8)	(39)
’23	(20)	(12)	(13)	(10)	(56)
’22	(4)	(9)	(12)	(10)	(35)
’21	(6)	(5)	(6)	(9)	(25)
’20	(4)	(4)	(4)	(7)	(19)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	—	—	1	4	6	5	5	5	6		+38.6%	4	3	4	(4.7%)
	Gross margin, %	100.00	100.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Armata Pharmaceuticals, Inc.’s next three years, line by line Analysts expect revenue to shrink 4.7% a year to 2028 — slower than the 38.6% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(19)	(14)	(17)	(19)	(22)	(23)	(37)	(69)	(19)	(174)	(192)		+27.6%
	EBT margin, %	(7,459.23)	(12,295.65)	0.00	0.00	(2,695.14)	(517.55)	(670.24)	(1,524.51)	(365.60)	(3,544.03)	(3,467.04)		+3,915.2 pt
	Net income	(19)	(13)	(17)	(19)	(22)	(23)	(37)	(69)	(19)	(174)	(192)		+28.0%
Per share, $
Per share, $	Revenue	3.70	0.25	0.00	0.00	0.05	0.19	0.16	0.13	0.14	0.14	0.15		(30.8%)
	Earnings	(345.94)	(28.15)	(3.59)	(2.49)	(1.35)	(0.96)	(1.08)	(1.91)	(0.52)	(4.80)	(5.31)		(37.8%)
	Cash flow	(150.87)	(20.16)	(2.28)	(1.99)	(1.11)	(0.98)	(0.95)	(1.31)	(1.04)	(0.71)	(0.69)		(44.9%)
	Capex	(3.97)	(0.13)	(0.17)	(0.02)	(0.05)	(0.05)	(0.06)	(0.23)	(0.05)	(0.01)	(0.01)		(46.2%)
	Free cash flow	(154.84)	(20.29)	(2.46)	(2.01)	(1.16)	(1.03)	(1.01)	(1.54)	(1.09)	(0.73)	(0.70)		(44.9%)
	Book value	138.31	16.95	1.65	1.86	1.15	1.05	1.05	(0.89)	(1.33)	(6.03)	(6.29)		n/m
	Shares, m	0	0	5	8	16	24	34	36	36	36	36		+100.2%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	18.36	56.07	—	—	58.03	29.52	6.85	24.69	9.98	46.41	22.34		31.2
	P/B	0.49	0.83	—	—	2.59	5.20	1.05	0.00	0.00	0.00	0.00		1.3
	EV/Sales	(3.60)	11.44	—	—	62.18	35.72	13.02	42.85	22.68	123.75	69.17		38.5
	EV/FCF	0.09	(0.14)	—	—	(2.75)	(6.42)	(2.07)	(3.49)	(3.85)	(23.07)	(14.86)		(5.2)
Cash, $m
Cash, $m	Operating cash flow	(11)	(9)	(11)	(16)	(18)	(24)	(32)	(47)	(38)	(26)	(25)		+10.4%
	Capex	0	0	(1)	0	(1)	(1)	(2)	(8)	(2)	(1)	0		+7.7%
	Free cash flow	(11)	(9)	(11)	(16)	(19)	(25)	(35)	(56)	(39)	(26)	(26)		+10.3%
Balance, $m
Balance, $m	Working capital	3	3	8	2	4	10	2	3	(37)	2	(223)		(5.2%)
	Net debt	(5)	(5)	(10)	(3)	4	28	34	69	85	248	260		n/m
	Shareholders’ equity	10	8	8	15	19	25	36	(32)	(48)	(219)	(231)		n/m
Returns, %
Returns, %	ROA	(97.80)	(87.66)	(130.06)	(97.40)	(68.28)	(42.38)	(44.59)	(71.11)	(20.47)	(212.83)	(225.11)		(115.0) pt
	ROIC	(303.45)	(388.51)	0.00	(108.07)	(60.34)	(28.04)	(32.97)	(69.60)	(71.53)	(77.26)	(89.61)		+226.2 pt
	ROE	(216.39)	(147.11)	(216.56)	(174.80)	(132.62)	(104.65)	(120.10)	(3,439.35)	47.24	130.37	127.83		+346.8 pt
People
People	Employees	33	34	31	38	62	71	75	66	60	61	—		+7.1%
	Revenue/emp, $m	0.01	0.00	0.00	0.00	0.01	0.06	0.07	0.07	0.09	0.08	—		+29.4%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CHRS Coherus Oncology, Inc.	$115.7M	— (loss-making)	— (loss-making)	+39.53% (above 0%: growing)	n/m	−33.15% (below 0%: shrinking)	70.35%	(225.98%)	Compare
PYPD PolyPid Ltd.	$115.2M	— (loss-making)	—	—	n/m	−64.96% (below 0%: shrinking)	0.00%	0.00%	Compare
FHTX Foghorn Therapeutics Inc.	$113.1M	— (loss-making)	— (loss-making)	+112.68% (above 0%: growing)	n/m	+14.88% (above 0%: growing)	100.00%	(54.78%)	Compare
ENGN enGene Therapeutics Inc	$112.6M	— (loss-making)	—	—	n/m	+28.07% (above 0%: growing)	—	0.00%	Compare
NKTX Nkarta, Inc.	$112.5M	— (loss-making)	—	—	n/m	−29.19% (below 0%: shrinking)	0.00%	0.00%	Compare
CDXS Codexis, Inc.	$111.7M	— (loss-making)	— (loss-making)	−2.69% (below 0%: shrinking)	n/m	+48.60% (above 0%: growing)	76.45%	(75.29%)	Compare
ARMP Armata Pharmaceuticals, Inc.	$111.5M	— (loss-making)	— (loss-making)	+15.72% (above 0%: growing)	n/m	−17.98% (below 0%: shrinking)	100.00%	(410.84%)
HUMA Humacyte, Inc.	$109.9M	— (loss-making)	— (loss-making)	+34.88% (above 0%: growing)	n/m	+17.85% (above 0%: growing)	(203.20%)	(6,649.26%)	Compare
NERV Minerva Neurosciences, Inc	$109.8M	— (loss-making)	— (loss-making)	—	n/m	−553.48% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$112.5M	—	—	+37.21%	—	−7.15%	0.00%	(27.39%)

All 621 Biotechnology stocks →

Armata Pharmaceuticals, Inc. (ARMP) Latest News

7 Oct

Impact 4 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

23 Sep

Impact 4 · 7:00 AM

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

21 Sep

Impact 3 · 7:00 AM · PR Newswire

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

14 Sep

Impact 4 · 9:34 AM · InvestorsHub

Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation

Impact 4 · 7:00 AM

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

3 Sep

Impact 3 · 7:00 AM

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

12 Aug

Impact 3 · 4:05 PM

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Impact 3 · 5:40 PM · Zacks

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

20 Jul

Impact 4 · 7:00 AM

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

13 Jul

Impact 3 · 7:00 AM

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

23 Jun

Impact 3 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

13 May

Impact 3 · 4:30 PM · PR Newswire

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

7 May

Impact 4 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

27 Apr

Impact 3 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors

25 Mar

Impact 3 · 4:05 PM · PR Newswire

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

2 Mar

Impact 4 · 10:23 AM · Insider Monkey

H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod

23 Feb

Impact 4 · 7:00 AM · PR NewswireProactive

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

13 Jan

Impact 4 · 7:00 AM · PR NewswireMT NewswiresMT NewswiresSimply Wall St.MT NewswiresExec EdgeMT Newswires

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

18 Nov

Impact 3 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

12 Nov

Impact 3 · 5:25 PM · Zacks

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Impact 3 · 4:05 PM · PR NewswireMT NewswiresZacksClinical Trials ArenaAssociated Press FinanceGuruFocus.comMotley Fool

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

10 Nov

Impact 4 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

23 Oct

Impact 3 · 7:10 AM · Zacks

Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

22 Oct

Impact 4 · 11:10 AM

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

14 Oct

Impact 4 · 7:00 AM · PR Newswire

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

6 Oct

Impact 3 · 9:40 AM · Zacks

Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?

18 Sep

Impact 3 · 9:40 AM

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

8 Sep

Impact 3 · 7:00 AM · PR Newswire

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

15 Aug

Impact 4 · 12:00 PM

All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy

Impact 4 · 9:40 AM · Zacks

Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Armata Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Armata Pharmaceuticals, Inc. (ARMP) Latest News

7 Oct

23 Sep

21 Sep

14 Sep

3 Sep

12 Aug

20 Jul

13 Jul

23 Jun

13 May

7 May

27 Apr

25 Mar

2 Mar

23 Feb

13 Jan

18 Nov

12 Nov

10 Nov

23 Oct

22 Oct

14 Oct

6 Oct

18 Sep

8 Sep

15 Aug

Stockrow Weekly